Alaunos Therapeutics Inc. (NASDAQ:TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003. Data ResultsThe latest findings from Alaunos indicate that ALN1003 has shown promising results in diet-induced obesity mouse studies, with treated mice experiencing a mean percent change in body weight loss of up to -12.9%.Peak reductions in absolute weight loss were observed by Day 13 and remained lower than DIO controls through Day 48.In the ...

The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated miceEfforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT), an ea ...